ClinicalTrials.gg
Sign In

DrugBiological

Anti-PD-1/Anti-VEGF Bispecific Antibody PF-08634404 clinical trials

Also written PF-08634404 and SSGJ-707.

studies test it
12
open now
12
in phase 3
6
first study started
2024

Keep track of what changes. Save the Anti-PD-1/Anti-VEGF Bispecific Antibody PF-08634404 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Development codes

PF-08634404
8
SSGJ-707
7

Studies by the year they started

12 studies that test it; most in 2026 (5)

Studies that test Anti-PD-1/Anti-VEGF Bispecific Antibody PF-08634404, by start year
YearStudies
20243
20254
20265

By phase

A phase 1/2 study counts in both.

Phase 1
2
Phase 2
8
Phase 3
6

What it is tested for

Each study’s main condition, where its own words name it.

Small Cell Lung Carcinoma
2
Colorectal Neoplasms
2
Endometrial Neoplasms
1
Stomach Neoplasms
1
Carcinoma, Hepatocellular
1
Carcinoma, Non-Small-Cell Lung
1

Who runs them

Industry 12 · Other 0

Pfizer (8) · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (3) · Shenyang Sunshine Pharmaceutical Co., LTD. (1)

Often tested with

Tested in the same studies.

Antineoplastic Agents (1) · Enfortumab vedotin (1) · Oxaliplatin (1) · Capecitabine (1) · Leucovorin (1) · Fluorouracil (1) · Pemetrexed (1) · Paclitaxel (1)

Studies

Open first, then newest update. How each study uses Anti-PD-1/Anti-VEGF Bispecific Antibody PF-08634404 is read from its arms, and is right about nine times in ten.

Testing it · 12

Given in every arm · 4 — Anti-PD-1/Anti-VEGF Bispecific Antibody PF-08634404 is usual care beside what is tested